Australian Breast Cancer Patients Want To Know About Costly Drugs
This article was originally published in PharmAsia News
Executive Summary
Breast cancer respondents to a survey in Australia overwhelmingly want their physicians to advise them about all new relevant drugs, regardless of their cost. The author of the survey said 96 percent of women said they wanted to be told about all drugs that could be used against their cancer. He said some oncologists often do not tell their patients about drugs that cost as much as $1,000 a week, but the survey said many patients said they were distressed when they found out other drugs had been available, even if they were expensive. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.